参芪扶正注射液对非小细胞肺癌患者化疗后生活质量的影响研究  

Clinical trial of Shenqi Fuzheng injection on quality of life in patients with non-small cell lung cancer after chemotherapy

作　　者：罗保平 周用[2] 曹婷[2] 左盼 蒋满红[2] LUO Bao-ping;ZHOU Yong;CAO Ting;ZUO Pan;JIANG Man-hong(The First Clinical College,Hubei University of Traditional Chinese Medicine,Wuhan 430061,China;Department of Oneology,Guanggu District,Hubei Provincial Hospital of Traditional Chinese Medicine,Wuhan 430000,China)

机构地区：[1]湖北中医药大学第一临床学院,武汉430061 [2]湖北省中医院光谷院区肿瘤科,武汉430000

出　　处：《中国临床药理学杂志》2018年第18期2137-2139,共3页The Chinese Journal of Clinical Pharmacology

摘　　要：目的观察参芪扶正注射液联合化疗对非小细胞肺癌患者的生活质量的改善效果。方法将96例非小细胞肺癌患者随机分为试验组(n=48)与对照组(n=48)。对照组第1天给予注射用顺铂75 mg·m^(^(-2)),静脉滴注2 h,第1,8天给予注射用吉西他滨1000 mg·m^(^(-2)),静脉滴注25 min;试验组在对照组的基础上,第1天开始给予参芪扶正注射液,静脉滴注。2组均21 d为1个周期,共治疗2个周期。比较2组患者治疗前后的近期疗效、Karnofsky评分、消化道不良反应食少纳呆症状积分及血液学毒性情况。结果治疗后,试验组和对照组的客观缓解率(ORR)分别为66.7%(32例/48例),58.3%(28例/48例),差异无统计学意义(P>0.05)。治疗后,试验组与对照组的Karnofsky评分分别为(60.04±11.52),(75.42±13.68)分;食少纳呆症状积分分别为(1.50±1.62),(2.29±1.60)分,差异均有统计学意义(均P<0.05)。试验组和对照组的Ⅲ/Ⅳ级血液学不良反应发生率分别为12.50%(6例/48例),25.00%(12例/48例),差异有统计学意义(P<0.05)。结论联合应用参芪扶正注射液能够减轻非小细胞肺癌患者化疗后消化道不良反应,提高生活质量,而不影响近期疗效。Objective To discuss the clinical effects of Shenqi Fuzheng injection combined with chemotherapy on quality of life（ QOL） in patients with non-small cell lung cancer（ NSCLC）. Methods Ninety-six cases of NSCLC were randomly divided into treatment group（ n = 48）and control group（ n = 48）. Patients in control group were treated with1000 mg·m^-2 gemcitabine on 1,8 d,75 mg·m^-2 cisplatin on day 1 by intravenous infusion. Treatment group was given Shenqi Fuzheng injection by intravenous infusion on day 1 on the basis of control group. All patients were 21 d a cycle,for 2 cycles. The short-term clinical effect,Karnofsky score,nastin score and hematological toxicity of the two groups were compared before and after treatment. Results After treatment,the objective response rate（ ORR） in treatment group and control group were 66. 7%（ 32 cases/48 cases）,58. 3%（ 28 cases/48 cases）,with no significant difference（ P〈0. 05）. After treatment,the Karnofsky scores in treatment group and control group were 60. 04 ± 11. 52,75. 42 ± 13. 68,the nastin score were 1. 50 ± 1. 62,2. 29 ± 1. 60,all with significant difference（ all P〈0. 05）. The Ⅲ/Ⅳ hematologic toxicity in treatmentgroup and control group were 12. 5%（ 6 cases/48 cases） and 25. 0%（ 12 cases/48 cases）,with significant difference（ P〈0. 05）. Conclusion Shenqi Fuzheng injection combined with chemotherapy didn＇t reduce recently effective rate,alleviate the gastrointestinal adverse reaction of chemotherapy,improve the QOL in patients with NSCLC.

关 键 词：参芪扶正注射液 化疗 非小细胞肺癌 生活质量 

分 类 号：R28[医药卫生—中药学]